AEON Biopharma (AEON) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 17, 2026, with voting on director elections and auditor ratification.

• The company is advancing ABP-450 in therapeutic indications for botulinum toxin, aiming for a capital-efficient development pathway.

• Proxy materials are delivered via a notice-only option, with full set delivery available upon request.

• Only Class A Common Stock holders as of April 21, 2026, are eligible to vote; 26,307,211 shares outstanding.

Voting matters and shareholder proposals

• Shareholders will vote to elect Marc Forth and Seongsoo Park as Class III directors until 2029.

• Ratification of KPMG LLP as the independent registered public accounting firm for 2026 is on the agenda.

• Shareholder proposals for the 2027 meeting must be submitted by December 30, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board consists of seven members divided into three classes, with staggered terms.

• Four directors are considered independent under NYSE American rules.

• The board has Audit, Compensation, and Nominating & Corporate Governance Committees, each with defined charters and responsibilities.

• The roles of Chairperson and CEO are separated; Jost Fischer serves as independent Chair.

• Board and committee meetings had high attendance in 2025, except for logistical challenges for one director.